Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

• The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Administration

Oral

Adult

Aged

Antibodies

Monoclonal

Humanized

administration & dosage

adverse effects

Antineoplastic Combined Chemotherapy Protocols

adverse effects

therapeutic use

Breast Neoplasms

chemistry

drug therapy

pathology

surgery

Chemotherapy

Adjuvant

Diarrhea

chemically induced

Drug Administration Schedule

Female

Humans

Infusions

Intravenous

Liver

drug effects

metabolism

Middle Aged

Neoadjuvant Therapy

methods

Paclitaxel

administration & dosage

adverse effects

Quinazolines

administration & dosage

adverse effects

Receptor

erbB-2

analysis

antagonists & inhibitors

Treatment Outcome

Tumor Markers

Biological

analysis

antagonists & inhibitors

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)